Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Alexandr V. Togo"'
Autor:
Sergey V. Orlov, Aglaya G. Iyevleva, Elena A. Filippova, Alexandra M. Lozhkina, Svetlana V. Odintsova, Tatiana N. Sokolova, Natalia V. Mitiushkina, Vladislav I. Tiurin, Elena V. Preobrazhenskaya, Alexandr A. Romanko, Alexandr S. Martianov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Alexandr V. Togo, Evgeny N. Imyanitov
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101121- (2021)
Background: Lorlatinib is a novel potent ALK inhibitor, with only a few studies reporting the results of its clinical use. Methods: This study describes the outcomes of lorlatinib treatment for 35 non-small cell lung cancer patients with ALK rearrang
Externí odkaz:
https://doaj.org/article/7a54773d24a54c3d9f4951da25379307
Autor:
Aglaya G. Iyevleva, Svetlana N. Aleksakhina, Anna P. Sokolenko, Sofia V. Baskina, Aigul R. Venina, Elena I. Anisimova, Ilya V. Bizin, Alexandr O. Ivantsov, Yana V. Belysheva, Alexandra P. Chernyakova, Alexandr V. Togo, Evgeny N. Imyanitov
Publikováno v:
Breast Cancer Research and Treatment. 192:283-291
Autor:
Alexandr O. Ivantsov, Natalia V. Mitiushkina, Tatiana N. Sokolova, Maxim M. Kholmatov, Ilya A. Stepanov, Vladislav I. Tiurin, Ekatherina Sh. Kuligina, Olga S. Yatsuk, Alexandr A. Romanko, Alexandr V. Togo, Alexey M. Belyaev, Evgeny N. Imyanitov
Publikováno v:
Biochimie. 165:267-274
MET exon 14 skipping (exon 14Δ) mutations are associated with tumor sensitivity to a number of tyrosine kinase inhibitors, however clinical testing for MET gene status remains complicated. We developed a simple allele-specific PCR cDNA-based test, w
Autor:
Aglaya G, Iyevleva, Svetlana N, Aleksakhina, Anna P, Sokolenko, Sofia V, Baskina, Aigul R, Venina, Elena I, Anisimova, Ilya V, Bizin, Alexandr O, Ivantsov, Yana V, Belysheva, Alexandra P, Chernyakova, Alexandr V, Togo, Evgeny N, Imyanitov
Publikováno v:
Breast cancer research and treatment. 192(2)
Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to identify the molecular characteristics of CHEK2-driven BCs.Loss of heterozygosity (LOH) for the rema
Autor:
Tatiana N. Sokolova, Evgeny N. Imyanitov, Sergey Orlov, Vladislav I. Tiurin, Alexandr A. Romanko, Svetlana N. Aleksakhina, Svetlana V. Odintsova, Alexandr S. Martianov, Elena A. Filippova, Alexandra M. Lozhkina, Natalia V. Mitiushkina, Aglaya G. Iyevleva, Alexandr O. Ivantsov, Elena V. Preobrazhenskaya, Alexandr V. Togo
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 8, Pp 101121-(2021)
Translational Oncology, Vol 14, Iss 8, Pp 101121-(2021)
Highlights • In patients with ALK-rearranged NSCLC who received lorlatinib within the compassionate use program, the objective tumor response (OR) and disease control (DC) were observed in 43% and 94% cases, respectively. • Lorlatinib showed part
Autor:
Alexandr O. Ivantsov, Anna P. Sokolenko, Elena V. Preobrazhenskaya, Alexandr S. Martianov, Svetlana A Chuinyshena, Olga A. Gorustovich, Alla U Shleykina, Tatjana N Sokolova, Alexandr V. Togo, Ekatherina Sh. Kuligina, Ilya V. Bizin, Elena I Anisimova, Evgeny N. Imyanitov, Alexey M. Belyaev
Publikováno v:
International journal of cancerREFERENCES. 148(1)
PALB2 is а high-penetrance gene for hereditary breast cancer (BC). Our study aimed to investigate the spectrum of PALB2 mutations in Russian cancer patients. PALB2 sequencing revealed pathogenic variants in 3/190 (1.6%) young-onset and/or familial a
Autor:
Elena I Anisimova, Ilya V. Bizin, Anna P. Sokolenko, Alexey M. Belyaev, Alexandr A. Bessonov, Svetlana N. Aleksakhina, Elena L. Savonevich, Tatiana N. Sokolova, Tatiana V. Gorodnova, Elena V. Preobrazhenskaya, Ilya A. Stepanov, Petr Krivorotko, Aglaya G. Iyevleva, Valeria I. Ni, Alexandr V. Togo, Evgeny N. Imyanitov, Alexandr A. Romanko, Igor Berlev
Publikováno v:
Breast cancer research and treatment. 184(1)
The spectrum of BRCA1 and BRCA2 mutations in Slavic countries is characterized by a high prevalence of founder alleles. We analyzed a large data set of Russian breast cancer (BC) and ovarian cancer (OC) patients, who were subjected to founder mutatio
Autor:
Tatyana N. Sokolova, Fedor V. Moiseyenko, Alexey A Kudriavtsev, Aglaya G. Iyevleva, Natalia V. Mitiushkina, Mikhail M Kramchaninov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Nikita M. Volkov, Elena V. Preobrazhenskaya, Kseniya S. Kozyreva, Kseniya V. Shelekhova, Ilya V. Bizin, Alexandr S. Zhuravlev, Ekatherina Sh. Kuligina, Aigul R. Venina, Evgeny N. Imyanitov, Denis V Pashkov, Anna P. Sokolenko, Vyacheslav A. Chubenko, Vladimir M. Moiseyenko, Alexandr V. Togo
Publikováno v:
Clinical Drug Investigation. 38:553-562
Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF). Most clinical trials for chemo-naive CRC p
Autor:
Elena D Lavdovskaia, Ilya V. Bizin, Nina Karaseva, I. Chistyakov, Fedor V. Moiseyenko, Ivan A Zaitsev, Anna P. Sokolenko, Andrey Akopov, Vladislav I. Tiurin, Andrey R Kozak, Natalia V. Mitiushkina, Alexandr V. Togo, Evgeny N. Imyanitov, Vladimir M. Moiseyenko, Sergey Orlov, Nikita M. Volkov, Marina A Korzhenevskaya, Liliya V Stelmakh, Alexandr O. Ivantsov, Elena V. Preobrazhenskaya, Aglaya G. Iyevleva
Publikováno v:
Oncology Research and Treatment. 41:634-642
Background: This study evaluated the distribution of epidermal growth factor receptor (EGFR) T790M mutations in treatment-naïve tumor and normal samples obtained from cancer patients. Methods: We utilized allele-specific PCR (AS-PCR), digital drople
Autor:
Alexandr O. Ivantsov, Sergey Orlov, Alexandr V. Togo, D. Kuznetsova, Evgeny N. Imyanitov, E. Levchenko, S. Baskina, O. Lopushanskaya, M. Maydin, S. Aleksakhina, I. Bizin, A. Kosmin
Publikováno v:
Journal of Thoracic Oncology. 16:S442-S443